[Skip to Navigation]
Sign In
Views 611
Citations 0
Comment & Response
August 5, 2021

Single-Dose Radiotherapy for Prostate Cancer—Lessons Learned From Single-Fraction High-Dose-Rate Brachytherapy

Author Affiliations
  • 1Department of Radiation Oncology, Beaumont Health, Royal Oak, Michigan
JAMA Oncol. 2021;7(10):1572. doi:10.1001/jamaoncol.2021.2691

To the Editor In their recent Original Investigation, Greco et al1 report early results from the PROSINT trial, which randomized 30 patients with intermediate-risk prostate cancer to 5-fraction stereotactic body radiotherapy (9 Gy × 5) vs 24-Gy single-dose radiotherapy (SDRT). After a median follow-up of 4 years, biochemical control rates were similar (86% vs 77%). As a proof-of-concept study, it forms the basis for larger, ongoing trials.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words